| Q38220879 | "RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway |
| Q35469515 | 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition |
| Q43543397 | A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal |
| Q27680863 | A Noncompetitive Inhibitor for Mycobacterium tuberculosis ’s Class IIa Fructose 1,6-Bisphosphate Aldolase |
| Q27671549 | A Novel Approach to the Discovery of Small-Molecule Ligands of CDK2 |
| Q46111608 | A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer |
| Q27667127 | A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK |
| Q92608964 | A Redox-Sensitive Thiol in Wis1 Modulates the Fission Yeast Mitogen-Activated Protein Kinase Response to H2O2 and Is the Target of a Small Molecule |
| Q37151025 | A chrysin derivative suppresses skin cancer growth by inhibiting cyclin-dependent kinases. |
| Q54595233 | A full-length 3D structure for MAPK/ERK kinase 2 (MEK2). |
| Q37976467 | A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets |
| Q39613897 | A novel mitogen-activated protein kinase docking site in the N terminus of MEK5alpha organizes the components of the extracellular signal-regulated kinase 5 signaling pathway. |
| Q35826693 | A novel role for copper in Ras/mitogen-activated protein kinase signaling |
| Q53389706 | A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. |
| Q28264038 | A quantitative analysis of kinase inhibitor selectivity |
| Q33591077 | A single polymorphic amino acid on Toxoplasma gondii kinase ROP16 determines the direct and strain-specific activation of Stat3. |
| Q27649303 | A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases |
| Q34756557 | ATP-noncompetitive CDK inhibitors for cancer therapy: an overview |
| Q48509895 | Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors |
| Q41955786 | Activation of a PAK-MEK signalling pathway in malaria parasite-infected erythrocytes |
| Q24309323 | Activation segment dimerization: a mechanism for kinase autophosphorylation of non-consensus sites |
| Q89006688 | Adiponectin attenuates kidney injury and fibrosis in deoxycorticosterone acetate-salt and angiotensin II-induced CKD mice |
| Q41815533 | Allosteric Communication Networks in Proteins Revealed through Pocket Crosstalk Analysis |
| Q33231742 | Allosteric inhibitors of Bcr-abl-dependent cell proliferation |
| Q28476718 | Allosteric interactions between the myristate- and ATP-site of the Abl kinase |
| Q38817910 | Allosteric modulators of MEK1: drug design and discovery |
| Q36973814 | Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy |
| Q38089896 | Alternative assay formats to identify diverse inhibitors of protein kinases |
| Q36243890 | Analysis of conditions affecting auto-phosphorylation of human kinases during expression in bacteria |
| Q30409158 | Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity |
| Q37605160 | Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics |
| Q37977357 | Autoregulation of kinase dephosphorylation by ATP binding in AGC protein kinases. |
| Q38498046 | BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma |
| Q27851610 | BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation |
| Q29614281 | BRAF mutation predicts sensitivity to MEK inhibition |
| Q35939402 | Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression |
| Q39873596 | Braf(V600E) cooperates with Pten loss to induce metastatic melanoma |
| Q36813976 | CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo |
| Q56262927 | Cancer drugs to treat birth defects |
| Q37833892 | Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. |
| Q37212411 | Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problem |
| Q38028557 | Cell-based apoptosis assays in oncology drug discovery |
| Q35020439 | Coffee phenolic phytochemicals suppress colon cancer metastasis by targeting MEK and TOPK |
| Q41693841 | Combined activation of MAP kinase pathway and β-catenin signaling cause deep penetrating nevi |
| Q28541231 | Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use |
| Q41863578 | Competing docking interactions can bring about bistability in the MAPK cascade |
| Q33944326 | Composition and applications of focus libraries to phenotypic assays |
| Q29616719 | Comprehensive analysis of kinase inhibitor selectivity |
| Q89738190 | Computational Analysis of Crystallization Additives for the Identification of New Allosteric Sites |
| Q31036423 | Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases |
| Q28256647 | Computer-aided drug design: the next 20 years |
| Q35700459 | Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF |
| Q35493874 | Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors. |
| Q42363492 | Constitutive MEK1 Activation Rescues Anthrax Lethal Toxin-Induced Vascular Effects In Vivo |
| Q28593521 | Control of mitotic spindle angle by the RAS-regulated ERK1/2 pathway determines lung tube shape |
| Q27664839 | Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition |
| Q27653598 | Crystal structure of domain-swapped STE20 OSR1 kinase domain |
| Q27663479 | Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain |
| Q37761333 | Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice |
| Q38248633 | Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey. |
| Q24672143 | Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach |
| Q33706073 | Delphinidin attenuates neoplastic transformation in JB6 Cl41 mouse epidermal cells by blocking Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling |
| Q37983986 | Designer proteins: applications of genetic code expansion in cell biology |
| Q47976445 | Detection of allosteric kinase inhibitors by displacement of active site probes |
| Q30382347 | Detection of secondary binding sites in proteins using fragment screening |
| Q50936315 | Determination of Structural Requirements of N-Substituted Tetrahydro-β-Carboline Imidazolium Salt Derivatives Using in Silico Approaches for Designing MEK-1 Inhibitors. |
| Q42983329 | Dimerization in protein kinase signaling |
| Q37666383 | Diminished WNT -> β-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors |
| Q36826875 | Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K) |
| Q27666837 | Discovery of a Potential Allosteric Ligand Binding Site in CDK2 |
| Q36862130 | Discovery of a novel allosteric inhibitor-binding site in ERK5: comparison with the canonical kinase hinge ATP-binding site |
| Q24294914 | Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors |
| Q92566519 | Druggable exosites of the human kino-pocketome |
| Q35207897 | Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor |
| Q26744787 | ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy? |
| Q33638827 | ETS-targeted therapy: can it substitute for MEK inhibitors? |
| Q30358225 | Emerging Computational Methods for the Rational Discovery of Allosteric Drugs. |
| Q37691441 | Emerging MEK inhibitors. |
| Q33971120 | Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity |
| Q40088825 | Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway |
| Q37565213 | Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). |
| Q26269893 | Evolution of CASK into a Mg2+-sensitive kinase |
| Q97567676 | Evolutionary chemical binding similarity approach integrated with 3D-QSAR method for effective virtual screening |
| Q27001584 | Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? |
| Q60238428 | Exploring Selectivity of Multikinase Inhibitors across the Human Kinome |
| Q92124140 | Expression Signatures of Cisplatin- and Trametinib-Treated Early-Stage Medaka Melanomas |
| Q30396809 | Fluorine–Protein Interactions and 19F NMR Isotropic Chemical Shifts: An Empirical Correlation with Implications for Drug Design |
| Q33698374 | From basic research to clinical development of MEK1/2 inhibitors for cancer therapy |
| Q34975272 | Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma |
| Q37113682 | Genetic predictors of MEK dependence in non-small cell lung cancer |
| Q35743316 | Genomic complexity and AKT dependence in serous ovarian cancer |
| Q38211688 | Harnessing allostery: a novel approach to drug discovery |
| Q24614202 | Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles |
| Q41916599 | Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2. |
| Q40657506 | Identification and characterization of a small-molecule inhibitor of death-associated protein kinase 1. |
| Q37383603 | Identification of a RAI1-associated disease network through integration of exome sequencing, transcriptomics, and 3D genomics. |
| Q35180343 | Identification of an In Vivo MEK/WOX1 Complex as a Master Switch for Apoptosis in T Cell Leukemia. |
| Q89752884 | Impact of the Protein Data Bank on antineoplastic approvals |
| Q92863081 | In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs |
| Q37033090 | Inactivation of rho GTPases by statins attenuates anthrax lethal toxin activity |
| Q44238904 | Inhibition of MAP2K and GSK3 signaling promotes bovine blastocyst development and epiblast-associated expression of pluripotency factors |
| Q28486286 | Inhibition of vascular smooth muscle cell proliferation by Gentiana lutea root extracts |
| Q36625236 | Inhibitors of signal transduction protein kinases as targets for cancer therapy |
| Q57807665 | Inhibitory-κB Kinase (IKK) α and Nuclear Factor-κB (NFκB)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets |
| Q58419536 | Insights into the Structural Basis of the GADD45β-mediated Inactivation of the JNK Kinase, MKK7/JNKK2 |
| Q33811883 | Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome |
| Q38238605 | Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer |
| Q91121996 | Investigation of Crystal Structures in Structure-Based Virtual Screening for Protein Kinase Inhibitors |
| Q48109284 | JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. |
| Q37815135 | KRAS and BRAF: drug targets and predictive biomarkers |
| Q48272267 | Kinase inhibitors: an allosteric add-on. |
| Q36997505 | Kinase packing defects as drug targets |
| Q33431755 | Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors |
| Q34467087 | MAP kinase modules: the excursion model and the steps that count |
| Q50292933 | MAP2Ks and MAPKs bind to the activated RAF complex |
| Q38092584 | MEK inhibitors as a chemotherapeutic intervention in multiple myeloma |
| Q39858584 | MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM. |
| Q47318847 | MEK inhibitors under development for treatment of non-small-cell lung cancer |
| Q92128564 | MEK nuclear localization promotes YAP stability via sequestering β-TrCP in KRAS mutant cancer cells |
| Q30441421 | MEK1 activation by PAK: a novel mechanism |
| Q38591835 | MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road |
| Q37160913 | MEK1 binds directly to betaarrestin1, influencing both its phosphorylation by ERK and the timing of its isoprenaline-stimulated internalization |
| Q27777362 | MEK1 mutations confer resistance to MEK and B-RAF inhibition |
| Q36328021 | MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms |
| Q42019758 | MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. |
| Q35990714 | MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism |
| Q37309967 | MEK4 function, genistein treatment, and invasion of human prostate cancer cells |
| Q43848612 | Manipulation of mitogen-activated protein kinase kinase signaling in the Arabidopsis stomatal lineage reveals motifs that contribute to protein localization and signaling specificity |
| Q27685364 | Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers |
| Q38007869 | Mechanisms of acquired resistance to ERK1/2 pathway inhibitors |
| Q36488752 | Mechanisms of drug inhibition of signalling molecules |
| Q27675436 | Mechanistic and Structural Understanding of Uncompetitive Inhibitors of Caspase-6 |
| Q34473609 | Mitogen-activated protein kinase (MAPK)-docking sites in MAPK kinases function as tethers that are crucial for MAPK regulation in vivo |
| Q39689442 | Mitogen-activated protein/extracellular signal-regulated kinase kinase 1act/tubulin interaction is an important determinant of mitotic stability in cultured HT1080 human fibrosarcoma cells |
| Q38821763 | Modular Assembly of Allosteric MEK Inhibitor Structural Elements Unravels Potency and Feedback-Modulation Handles |
| Q37843462 | Molecular targets of phytochemicals for cancer prevention |
| Q54392173 | Multiple café au lait spots in familial patients with MAP2K2 mutation. |
| Q37301530 | Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression. |
| Q36654909 | New approaches to molecular cancer therapeutics |
| Q40076565 | New small-molecule inhibitors of mitogen-activated protein kinase kinase |
| Q27684146 | Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973) |
| Q36980836 | Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma |
| Q88797879 | Novel Nitric Oxide Donors of Phenylsulfonylfuroxan and 3-Benzyl Coumarin Derivatives as Potent Antitumor Agents |
| Q39226865 | Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases |
| Q37828536 | Novel mitogen-activated protein kinase kinase inhibitors |
| Q40965918 | Novel zebrafish model reveals a critical role for MAPK in lymphangiogenesis |
| Q39589034 | Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation |
| Q34552000 | Optical control of cell signaling by single-chain photoswitchable kinases |
| Q36812355 | Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies |
| Q37696259 | PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK |
| Q37687519 | Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases |
| Q38491964 | Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer |
| Q34001269 | Probing the probes: fitness factors for small molecule tools |
| Q92237404 | Prospects for pharmacological targeting of pseudokinases |
| Q37181827 | Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways |
| Q37417742 | Protein kinase inhibitors: contributions from structure to clinical compounds |
| Q37389046 | Protein promiscuity and its implications for biotechnology |
| Q36512011 | Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine |
| Q33646519 | Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target |
| Q35679353 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health |
| Q37624361 | Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. |
| Q36851665 | Reconstitution of modular PDK1 functions on trans-splicing of the regulatory PH and catalytic kinase domains |
| Q27973811 | Regulation of Plasmodium falciparum Pfnek3 relies on phosphorylation at its activation loop and at threonine 82 |
| Q53562530 | Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. |
| Q35558850 | Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity. |
| Q34417585 | Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. |
| Q28301942 | Role of mitogen-activated protein kinase kinase 4 in cancer |
| Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
| Q27689430 | Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors |
| Q54310457 | Selumetinib for the treatment of cancer. |
| Q37914630 | Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma |
| Q42341423 | Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma |
| Q38747573 | Signaling pathways as therapeutic targets in biliary tract cancer. |
| Q52098928 | Silymarin and its active component silibinin act as novel therapeutic alternatives for salivary gland cancer by targeting the ERK1/2-Bim signaling cascade. |
| Q38090664 | Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition |
| Q39817347 | Specific phosphorylation and activation of ERK1c by MEK1b: a unique route in the ERK cascade |
| Q47279069 | Specificity of phosphorylation responses to MAP kinase pathway inhibitors in melanoma cells |
| Q46607689 | Strategies for the NMR-based identification and optimization of allosteric protein kinase inhibitors |
| Q27653949 | Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor Design |
| Q39660467 | Structural Studies of MAP Kinase Cascade Components |
| Q30368586 | Structural and biochemical insights into the activation mechanisms of germinal center kinase OSR1. |
| Q99413719 | Structural basis for the action of the drug trametinib at KSR-bound MEK |
| Q41749934 | Structural basis of autoregulatory scaffolding by apoptosis signal-regulating kinase 1. |
| Q21562307 | Structural requirements for Yersinia YopJ inhibition of MAP kinase pathways |
| Q24302450 | Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling |
| Q47760790 | Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168). |
| Q39148610 | Substituted 3-benzylcoumarins as allosteric MEK1 inhibitors: design, synthesis and biological evaluation as antiviral agents. |
| Q39063433 | Synthesis and biological evaluation of RGD-conjugated MEK1/2 kinase inhibitors for integrin-targeted cancer therapy |
| Q47660354 | Synthesis of piperazine-based thiazolidinones as VEGFR2 tyrosine kinase inhibitors inducing apoptosis. |
| Q91632717 | Targeting Alterations in the RAF-MEK Pathway |
| Q36546429 | Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer |
| Q34146883 | Targeting Pyk2 for therapeutic intervention |
| Q29547395 | Targeting cancer with small molecule kinase inhibitors |
| Q37629722 | Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors |
| Q38388217 | Targeting of MEK in lung cancer therapeutics |
| Q42020468 | Targeting oncogenic BRAF in human cancer |
| Q33671660 | Targeting protein kinases in central nervous system disorders |
| Q36486780 | Targeting the ERK signaling pathway in cancer therapy |
| Q50026949 | Targeting the MAPK Pathway in RAS Mutant Cancers |
| Q29618155 | Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer |
| Q51609396 | Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary. |
| Q37753517 | Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response |
| Q38090668 | Targeting the unactivated conformations of protein kinases for small molecule drug discovery |
| Q26849417 | Ten things you should know about protein kinases: IUPHAR Review 14 |
| Q54933459 | The (un)targeted cancer kinome |
| Q33730358 | The Design, Annotation, and Application of a Kinase-Targeted Library |
| Q34106720 | The MEK2-binding tumor suppressor hDlg is recruited by E-cadherin to the midbody ring |
| Q24318533 | The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation |
| Q37159467 | The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders |
| Q36434923 | The Salmonella kinase SteC targets the MAP kinase MEK to regulate the host actin cytoskeleton |
| Q27653414 | The Structure of the MAP2K MEK6 Reveals an Autoinhibitory Dimer |
| Q38270129 | The biology and clinical development of MEK inhibitors for cancer |
| Q38212717 | The clinical development of MEK inhibitors |
| Q30413381 | The distribution of ligand-binding pockets around protein-protein interfaces suggests a general mechanism for pocket formation |
| Q37022473 | The resveratrol analogue 3,5,3',4',5'-pentahydroxy-trans-stilbene inhibits cell transformation via MEK |
| Q24657537 | The structural basis of arrestin-mediated regulation of G-protein-coupled receptors |
| Q47345032 | The target landscape of clinical kinase drugs |
| Q37837732 | Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. |
| Q91865432 | Time-resolved protein activation by proximal decaging in living systems |
| Q37856294 | Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases |
| Q39409731 | Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling |
| Q34559750 | Tunable signal processing in synthetic MAP kinase cascades |
| Q42672174 | Tyrosine kinase 4 is involved in the reproduction of the platyhelminth parasite Schistosoma japonicum |
| Q36494279 | Unique MAP Kinase binding sites |
| Q35447701 | Yeast two-hybrid junk sequences contain selected linear motifs |
| Q27649203 | c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations |